Impact of reactive changes on multigene testing: Histopathologic analysis of low-grade breast cancers with high-risk 21-gene recurrence scores Journal Article
| Authors: | Grabenstetter, A.; Brogi, E.; Thompson, D. M.; Blinder, V. S.; Norton, L.; Morrow, M.; Robson, M. E.; Wen, H. Y. |
| Article Title: | Impact of reactive changes on multigene testing: Histopathologic analysis of low-grade breast cancers with high-risk 21-gene recurrence scores |
| Abstract: | Purpose: The 21-gene recurrence score (RS) assay predicts the recurrence risk and magnitude of chemotherapy benefit in patients with invasive breast cancer (BC). This study examined low-grade tumors yielding a high-risk RS and their outcomes. Kindly check the edit made in the article title Ok Methods: We compared patients with grade 1 BC and a high-risk RS to those with low-risk RS. Histologic sections were reviewed and features reported to elevate the RS were noted, mainly biopsy cavity and reactive stromal changes (BXC). Results: A total of 54 patients had high-risk RS (median RS of 28, range 26–36). On review, BXC were seen in all cases. Thirty BCs in this group also had low to negative PR. Treatment regimens included: chemoendocrine therapy (63%), endocrine therapy alone (31%) and no adjuvant therapy (6%). There were no additional breast cancer events over a median follow-up of 54.0 months (range 6.2 to 145.3). A total of 108 patients had low-risk RS (median RS of 7, range 0–9). BXC were seen in 47% of cases and none were PR negative. One patient had a recurrence at 64.8 months while the rest had no additional events over a median of 68.1 months (2.4 to 100). Conclusion: We provide further evidence that reactive stromal changes and/or low-PR scores enhance the elevation of the RS. A high-RS result in low grade, PR-positive BC may not reflect actual risk and any suspected discrepancies should be discussed with the management teams. Multigene testing results should be interpreted after correlation with pathologic findings to optimize patient care. Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Author 1 Given name: [specify authors given name] Last name [specify authors last name]. Also, kindly confirm the details in the metadata are correct. © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| Keywords: | adult; cancer chemotherapy; controlled study; human tissue; aged; disease-free survival; major clinical study; genetics; histopathology; cancer recurrence; multimodality cancer therapy; cancer adjuvant therapy; cancer patient; disease free survival; combined modality therapy; chemotherapy; follow up; cancer grading; neoplasm recurrence, local; breast cancer; breast; cohort analysis; tumor biopsy; pathology; breast neoplasms; retrospective study; tumor marker; histology; high risk patient; cancer hormone therapy; cancer genetics; patient care; tumor recurrence; breast tumor; scoring system; stroma; receptors, estrogen; estrogen receptor; genetic screening; multigene family; low risk patient; desmoplasia; humans; prognosis; human; female; article; recurrence score; biomarkers, tumor; 21 gene recurrence score; biopsy site changes |
| Journal Title: | Breast Cancer Research and Treatment |
| Volume: | 203 |
| Issue: | 1 |
| ISSN: | 0167-6806 |
| Publisher: | Springer |
| Date Published: | 2024-01-01 |
| Start Page: | 153 |
| End Page: | 161 |
| Language: | English |
| DOI: | 10.1007/s10549-023-07127-3 |
| PUBMED: | 37768520 |
| PROVIDER: | scopus |
| PMCID: | PMC11165372 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in PubMed and PDF -- Corresponding author is MSK author: Anne Grabenstetter -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work